The Australian share market certainly is not short of blue chips. But which ones should you buy over others?
To help narrow things down, listed below are two top blue chip ASX 200 shares that are rated as buys by experts. They are as follows:
CSL Limited (ASX: CSL)
The first blue chip ASX 200 share to consider is CSL. It is one of the world's leading biotechnology companies and the name behind the CSL Behring and Seqirus businesses. CSL Behring is the global leader in a plasma therapies industry, whereas Seqirus is the number two player in the global influenza vaccines industry.
CSL has also just completed the acquisition of Vifor Pharma. This business, now known as CSL Vifor, is the global specialty pharmaceutical leader in iron deficiency, nephrology (kidney care), and cardio-renal therapies.
All three businesses appear well-placed for growth over the long term thanks to their high quality products and lucrative research and development pipelines. In addition, improving plasma collection conditions should be a boost to the company's margins in the near term.
Citi is positive on CSL and currently has a buy rating and $340.00 price target on its shares.
Goodman Group (ASX: GMG)
Another blue chip ASX 200 share that has been tipped as a buy is Goodman Group.
It is a leading integrated commercial and industrial property company with a portfolio of high quality properties. Many of these properties have exposure to key growth markets such as ecommerce and logistics where demand is particularly strong. This has underpinned stellar earnings growth in recent years.
The team at Goldman Sachs believes that this strong form can continue thanks to "a number of favourable fundamentals underpinning future long-term demand for industrial space." For example, it expects this to lead to operating earnings per share growth of ~17% in FY 2023.
Goldman has a buy rating and $25.40 price target on its shares.
